

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
12 December 2024 (12.12.2024)




(10) International Publication Number  
**WO 2024/254052 A1**

- (51) **International Patent Classification:**  
*C12N 15/864* (2006.01) *A61K 48/00* (2006.01)  
*C12N 7/00* (2006.01) *C12N 15/113* (2010.01)
- (21) **International Application Number:**  
PCT/US2024/032381
- (22) **International Filing Date:**  
04 June 2024 (04.06.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
63/507,266 09 June 2023 (09.06.2023) US
- (71) **Applicant: 4D MOLECULAR THERAPEUTICS INC.**  
[US/US]; 5858 Horton Street, Suite 455, Emeryville, California 94608 (US).
- (72) **Inventors: BARGLOW, Catherine T.;** c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, California 94608 (US). **GONZALES, Johnny**
- C.; 5858 Horton Street, Suite 455, Emeryville, California 94608 (US).
- (74) **Agent: CABRAL, Christopher M.;** Much Shelist PC, 191 N. Wacker Drive, Suite 1800, Chicago, Illinois 60606 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) **Title: ADENO-ASSOCIATED VIRUS FORMULATIONS**

FIG. 1



| Form | Description                           |
|------|---------------------------------------|
| 1    | GPBE                                  |
| 2    | 30 mM Na Phosphate, pH 7, 150 mM NaCl |
| 3    | 30 mM Na Phosphate, pH 7, 150 mM NaCl |
| 4    | 10 mM Histidine, pH 6, 150 mM NaCl    |
| 5    | 10 mM Tris, pH 8, 150 mM NaCl         |

All formulations contain 0.005% F68.

(57) **Abstract:** Pharmaceutical compositions comprising adeno-associated virus (AAV) are provided herein. In some aspects, the pharmaceutical compositions comprise about 5 mM to about 20 mM Tris buffer, about 100 mM to about 250 mM sodium chloride, about 0.001 % (w/v) to about 0.01 % (w/v) Pluronic F68, and has a pH between 7.0 and 9.0. Methods of preparing a pharmaceutical composition comprising AAV, methods of treating a VEGF-associated disorder in a subject, and methods of storing AAV compositions are also provided.

[Continued on next page]

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*